Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2021/058104, filed Nov 4, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,628,218 | Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof In force · Medium confidence | Create Medicines, Inc. | In force | Medium confidence | ||
| US 11,944,680 | Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof In force · Low confidence | Create Medicines, Inc. | In force | Low confidence | ||
| Application 18/434,220 | Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof Pending Not granted | Create Medicines, Inc. | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Create Medicines, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.